Curated News
By: NewsRamp Editorial Staff
January 02, 2025
Investors Alert: Securities Class Action Lawsuit Against Kyverna Therapeutics, Inc.
Discuss on Reddit
LinkedIn
TelegramTLDR
- Investors can gain advantage in securities fraud class action against Kyverna Therapeutics, Inc. by becoming lead plaintiff before February 7, 2025.
- Investors who purchased Kyverna common stock during its February 8, 2024 IPO may seek lead plaintiff representation through Kessler Topaz Meltzer & Check, LLP.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from fraud, abuse, and negligence by businesses, seeking justice for victims of corporate misconduct.
- Kyverna Therapeutics, Inc. faces securities class action lawsuit due to alleged false statements about adverse data related to one of its clinical trials post IPO.
Impact - Why it Matters
This news is significant for investors who purchased Kyverna common stock during its IPO, as it highlights alleged false statements made by the company. Investors have the opportunity to seek appointment as a lead plaintiff and potentially recover losses. It serves as a reminder of the importance of due diligence and transparency in the financial markets.
Summary
The law firm of Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Kyverna Therapeutics, Inc. on behalf of investors who purchased Kyverna common stock during its IPO. The complaint alleges that Kyverna made false statements regarding adverse data related to one of its clinical trials at the time of the IPO. Investors have until February 7, 2025, to seek appointment as a lead plaintiff through Kessler Topaz Meltzer & Check, LLP.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Investors Alert: Securities Class Action Lawsuit Against Kyverna Therapeutics, Inc.
